Literature DB >> 28771675

Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.

Preetesh Jain1, Rashmi Kanagal-Shamanna2, F Anthony San Lucas2, Loretta Nastoupil3, Jorge Romaguera3, Luis Fayad3, Yasuhiro Oki3, Jason R Westin3, Leonard Jeffrey Medeiros2, Michael Wang3, Nathan Fowler3.   

Abstract

Entities:  

Keywords:  Bruton tyrosine kinase; follicular lymphoma; ibrutinib

Mesh：

Substances：

Year:  2017        PMID： 28771675      PMCID： PMC5904008          DOI： 10.1111/bjh.14857

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Authors:  Inhye E Ahn; Chingiz Underbayev; Adam Albitar; Sarah E M Herman; Xin Tian; Irina Maric; Diane C Arthur; Laura Wake; Stefania Pittaluga; Constance M Yuan; Maryalice Stetler-Stevenson; Susan Soto; Janet Valdez; Pia Nierman; Jennifer Lotter; Liqiang Xi; Mark Raffeld; Mohammed Farooqui; Maher Albitar; Adrian Wiestner
Journal:  Blood       Date:  2017-01-03       Impact factor: 22.113

2.  Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.

Authors:  Kilannin Krysiak; Felicia Gomez; Brian S White; Matthew Matlock; Christopher A Miller; Lee Trani; Catrina C Fronick; Robert S Fulton; Friederike Kreisel; Amanda F Cashen; Kenneth R Carson; Melissa M Berrien-Elliott; Nancy L Bartlett; Malachi Griffith; Obi L Griffith; Todd A Fehniger
Journal:  Blood       Date:  2016-11-14       Impact factor: 22.113

3.  BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Authors:  Cristina Correia; Paula A Schneider; Haiming Dai; Ahmet Dogan; Matthew J Maurer; Amy K Church; Anne J Novak; Andrew L Feldman; Xiaosheng Wu; Husheng Ding; X Wei Meng; James R Cerhan; Susan L Slager; William R Macon; Thomas M Habermann; Judith E Karp; Steven D Gore; Neil E Kay; Diane F Jelinek; Thomas E Witzig; Grzegorz S Nowakowski; Scott H Kaufmann
Journal:  Blood       Date:  2014-12-01       Impact factor: 22.113

4.  Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.

Authors:  Preetesh Jain; Michael Keating; William Wierda; Zeev Estrov; Alessandra Ferrajoli; Nitin Jain; Binsah George; Danelle James; Hagop Kantarjian; Jan Burger; Susan O'Brien
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

5.  Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.

Authors:  David Chiron; Maurizio Di Liberto; Peter Martin; Xiangao Huang; Jeff Sharman; Pedro Blecua; Susan Mathew; Priyanka Vijay; Ken Eng; Siraj Ali; Amy Johnson; Betty Chang; Scott Ely; Olivier Elemento; Christopher E Mason; John P Leonard; Selina Chen-Kiang
Journal:  Cancer Discov       Date:  2014-07-31       Impact factor: 39.397

6.  Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Authors:  John C Byrd; Bonnie Harrington; Susan O'Brien; Jeffrey A Jones; Anna Schuh; Steve Devereux; Jorge Chaves; William G Wierda; Farrukh T Awan; Jennifer R Brown; Peter Hillmen; Deborah M Stephens; Paolo Ghia; Jacqueline C Barrientos; John M Pagel; Jennifer Woyach; Dave Johnson; Jane Huang; Xiaolin Wang; Allard Kaptein; Brian J Lannutti; Todd Covey; Maria Fardis; Jesse McGreivy; Ahmed Hamdy; Wayne Rothbaum; Raquel Izumi; Thomas G Diacovo; Amy J Johnson; Richard R Furman
Journal:  N Engl J Med       Date:  2015-12-07       Impact factor: 91.245

7.  Postibrutinib outcomes in patients with mantle cell lymphoma.

Authors:  Peter Martin; Kami Maddocks; John P Leonard; Jia Ruan; Andre Goy; Nina Wagner-Johnston; Simon Rule; Ranjana Advani; David Iberri; Tycel Phillips; Stephen Spurgeon; Eliana Kozin; Katherine Noto; Zhengming Chen; Wojciech Jurczak; Rebecca Auer; Ewa Chmielowska; Stephan Stilgenbauer; Johannes Bloehdorn; Craig Portell; Michael E Williams; Martin Dreyling; Paul M Barr; Selina Chen-Kiang; Maurizio DiLiberto; Richard R Furman; Kristie A Blum
Journal:  Blood       Date:  2016-01-13       Impact factor: 22.113

Review 8.  Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.

Authors:  M A Lunning; M R Green
Journal:  Blood Cancer J       Date:  2015-10-16       Impact factor: 11.037

9.  Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.

Authors:  Jan A Burger; Dan A Landau; Amaro Taylor-Weiner; Ivana Bozic; Huidan Zhang; Kristopher Sarosiek; Lili Wang; Chip Stewart; Jean Fan; Julia Hoellenriegel; Mariela Sivina; Adrian M Dubuc; Cameron Fraser; Yulong Han; Shuqiang Li; Kenneth J Livak; Lihua Zou; Youzhong Wan; Sergej Konoplev; Carrie Sougnez; Jennifer R Brown; Lynne V Abruzzo; Scott L Carter; Michael J Keating; Matthew S Davids; William G Wierda; Kristian Cibulskis; Thorsten Zenz; Lillian Werner; Paola Dal Cin; Peter Kharchencko; Donna Neuberg; Hagop Kantarjian; Eric Lander; Stacey Gabriel; Susan O'Brien; Anthony Letai; David A Weitz; Martin A Nowak; Gad Getz; Catherine J Wu
Journal:  Nat Commun       Date:  2016-05-20       Impact factor: 14.919
  9 in total
  1 in total

1.  Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.

Authors:  Alessio Bruscaggin; Lodovico Terzi di Bergamo; Valeria Spina; Brendan Hodkinson; Gabriela Forestieri; Ferdinando Bonfiglio; Adalgisa Condoluci; Wei Wu; Maria C Pirosa; Martin R Faderl; Ricardo Koch; Michael Schaffer; John D Alvarez; Nele Fourneau; Bernhard Gerber; Georg Stussi; Emanuele Zucca; Sriram Balasubramanian; Davide Rossi
Journal:  Blood Adv       Date:  2021-11-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.